Literature DB >> 7008885

Effect of indomethacin on hydralazine-induced renin and catecholamine release in the conscious rabbit.

W B Campbell, R M Graham, E K Jackson, D P Loisel, W A Pettinger.   

Abstract

1. The effects of hydralazine on mean arterial pressure (MAP) heart rate (HR), plasma renin activity (PRA) and plasma catecholamines were examined in conscious rabbits before and after prostaglandin synthesis inhibition with indomethacin. 2. Hydralazine (3 mg/kg. i.v.) produced a 12% decrease in MAP and significant increases in HR, PRA and plasma noradrenaline and adrenaline. 3. Indomethacin (5 mg/kg, s.c.) failed to alter significantly the control MAP, HR, PRA or plasma catecholamines but inhibited renal venous prostaglandin E2 by 56% (P less than 0.02). 4. Indomethacin inhibited the hydralazine-induced tachycardia by 24% and augmented its hypotensive effects by 6%. 5. The hydralazine-stimulated increase in PRA was also inhibited 75% (P less than 0.001) by indomethacin whereas noradrenaline and adrenaline concentrations were not significantly reduced. 6. Indomethacin inhibits hydralazine-induced renin release in the presence of elevated concentrations of plasma catecholamines; these findings suggest that renal prostaglandins function as important mediators of sympathetically-induced renin release.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7008885      PMCID: PMC2044447          DOI: 10.1111/j.1476-5381.1980.tb10968.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  12 in total

1.  Alpha and beta adrenergic-induced renin release in man.

Authors:  F H Leenen; D P Redmond; R H McDonald
Journal:  Clin Pharmacol Ther       Date:  1975-07       Impact factor: 6.875

2.  Evidence for prostaglandin mediated prejunctional control of renal sympathetic transmitter release and vascular tone.

Authors:  M H Frame; P Hedqvist
Journal:  Br J Pharmacol       Date:  1975-06       Impact factor: 8.739

3.  Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine.

Authors:  J D Peuler; G A Johnson
Journal:  Life Sci       Date:  1977-09-01       Impact factor: 5.037

4.  An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody.

Authors:  K Poulsen; J Jorgensen
Journal:  J Clin Endocrinol Metab       Date:  1974-11       Impact factor: 5.958

5.  Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine.

Authors:  T B Gottlieb; F H Katz; C A Chidsey
Journal:  Circulation       Date:  1972-03       Impact factor: 29.690

6.  Adrenergic component of renin release induced by vasodilating antihypertensive drugs in the rat.

Authors:  W A Pettinger; W B Campbell; K Keeton
Journal:  Circ Res       Date:  1973-07       Impact factor: 17.367

7.  Effects of catecholamines and renal nerve stimulation on renin release in the nonfiltering kidney.

Authors:  J A Johnson; J O Davis; R T Witty
Journal:  Circ Res       Date:  1971-12       Impact factor: 17.367

8.  Potentiation and abolition of the increase in plasma renin activity seen after hypotensive drugs in rats.

Authors:  D K Meyer; B Peskar; U Tauchmann; G Hertting
Journal:  Eur J Pharmacol       Date:  1971 Nov-Dec       Impact factor: 4.432

9.  Altered renin release and propranolol potentiation of vasodilatory drug hypotension.

Authors:  W A Pettinger; K Keeton
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

10.  Radioimmunoassay of prostaglandins Falpha, E1 and E2 in human plasma.

Authors:  F Dray; B Charbonnel; J Maclouf
Journal:  Eur J Clin Invest       Date:  1975-07-29       Impact factor: 4.686

View more
  2 in total

1.  Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug.

Authors:  T Münzel; S Kurz; S Rajagopalan; M Thoenes; W R Berrington; J A Thompson; B A Freeman; D G Harrison
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

Review 2.  Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease.

Authors:  Peter Fraisl; Julián Aragonés; Peter Carmeliet
Journal:  Nat Rev Drug Discov       Date:  2009-01-23       Impact factor: 84.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.